{
    "organizations": [],
    "uuid": "111a73bffb4cab69a24a3fdfeee6e33b8c8f52d2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-axsome-therapeutics-reports-q1-los/brief-axsome-therapeutics-reports-q1-loss-per-share-of-0-19-idUSASC0A0EL",
    "ord_in_thread": 0,
    "title": "BRIEF-Axsome Therapeutics Reports Q1 Loss Per Share Of $0.19",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Axsome Therapeutics Inc:\n* AXSOME THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* Q1 LOSS PER SHARE $0.19 * AT MARCH 31, 2018, AXSOME HAD $26.6 MILLION OF CASH COMPARED TO $34.0 MILLION OF CASH AT DECEMBER 31, 2017\n* BELIEVES CURRENT CASH WILL BE SUFFICIENT TO FUND OPERATIONS, BASED ON CURRENT OPERATING PLANS, INTO Q3 OF 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-08T19:30:00.000+03:00",
    "crawled": "2018-05-09T12:32:11.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "axsome",
        "therapeutic",
        "inc",
        "axsome",
        "therapeutic",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "business",
        "update",
        "q1",
        "loss",
        "per",
        "share",
        "march",
        "axsome",
        "million",
        "cash",
        "compared",
        "million",
        "cash",
        "december",
        "belief",
        "current",
        "cash",
        "sufficient",
        "fund",
        "operation",
        "based",
        "current",
        "operating",
        "plan",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}